{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:57:17Z","timestamp":1790668637079,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited data on factors predicting the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs\/tsDMARDs) in Spondyloarthritis (SpA) and Psoriatic arthritis (PsA). The relative importance of objective inflammation and other patient factors in this context is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study included consecutive patients diagnosed with SpA and PsA in 2012\u20132016 at a single rheumatology center. Data at diagnosis were obtained from medical records and from linkage to national and regional registers. Baseline predictors of b\/tsDMARD initiation were assessed by Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 119 PsA patients (mean age 49\u2009years, 49% male), 41.7% initiated b\/tsDMARDs (median 15\u2009months after diagnosis). In patients with PsA, older age was negatively associated with b\/tsDMARD initiation (hazard ratio (HR) per standard deviation 0.74; 95% confidence interval (CI) 0.55\u20131.00), but no other significant predictors were identified. Among 120 SpA patients (mean age 38\u2009years, 64% male), 41.5% initiated bDMARDs (median 7\u2009months after diagnosis). Predictors included elevated CRP levels (HR 2.68; 95% CI 1.44\u20135.01) and bone marrow edema (BME) on magnetic resonance imaging of sacroiliac joints (SIJ) (HR 1.94; 95% CI 1.02\u20133.70). There was no significant association with age at SpA diagnosis, or with sex, education, family background, country of birth, or comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated CRP and SIJ BME at diagnosis were associated with bDMARD initiation in patients with SpA, while older patients with PsA may be less likely to start b\/tsDMARDs. Education and ethnicity did not seem to influence b\/tsDMARD initiation, suggesting equitable treatment access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-026-00698-w","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:44:18Z","timestamp":1790664258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors at diagnosis for initiation of biologic or targeted synthetic disease-modifying anti-rheumatic drugs in patients with spondyloarthritis and psoriatic arthritis"],"prefix":"10.1186","volume":"10","author":[{"given":"Mohaned A.","family":"Hameed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Exarchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Einarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"6","key":"698_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760\u201374. https:\/\/doi.org\/10.1136\/ard-2024-225534.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"698_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198\u2013206. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"698_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American college of Rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399. https:\/\/doi.org\/10.1002\/acr.24025.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"698_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American college of Rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332. https:\/\/doi.org\/10.1002\/art.40726.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"698_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319. https:\/\/doi.org\/10.1136\/ard-2024-225531.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"698_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296.","journal-title":"Ann Rheum Dis"},{"key":"698_CR7","doi-asserted-by":"publisher","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl, 2):ii1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018.","DOI":"10.1136\/ard.2008.104018"},{"issue":"8","key":"698_CR8","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"698_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/03009742.2014.927918","volume":"44","author":"H Wadstr\u00f6m","year":"2015","unstructured":"Wadstr\u00f6m H, Eriksson JK, Neovius M, Askling J, Behalf of the Artis Study Group ON. How good is the coverage and how accurate are exposure data in the Swedish biologics Register (ARTIS)? Scand J Rheumatol. 2015;44(1):22\u201328. https:\/\/doi.org\/10.3109\/03009742.2014.927918.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"698_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","volume":"80","author":"V Molander","year":"2021","unstructured":"Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169\u201375. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218419.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"698_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1403494819868042","volume":"48","author":"S L\u00f6fvendahl","year":"2020","unstructured":"L\u00f6fvendahl S, Schelin MEC, J\u00f6ud A. The value of the Sk\u00e5ne health-care Register: prospectively collected individual-level data for population-based studies. Scand J Public Health. 2020;48(1):56\u201363. https:\/\/doi.org\/10.1177\/1403494819868042.","journal-title":"Scand J Public Health"},{"key":"698_CR12","doi-asserted-by":"publisher","unstructured":"Hameed M, Exarchou S, Eberhard A, Sharma A, Bergstr\u00f6m U, Cagnotto G, et al. Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study. BMJ Open. 2024;14(2):e076131. https:\/\/doi.org\/10.1136\/bmjopen-2023-076131.","DOI":"10.1136\/bmjopen-2023-076131"},{"issue":"3","key":"698_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/rheumatology\/kead278","volume":"63","author":"A Eberhard","year":"2024","unstructured":"Eberhard A, Bergman S, Mandl T, Olofsson T, Sharma A, Turesson C. Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients. Rheumatol (Oxford). 2024;63(3):734\u201341. https:\/\/doi.org\/10.1093\/rheumatology\/kead278.","journal-title":"Rheumatol (Oxford)"},{"issue":"6","key":"698_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"698_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"4","key":"698_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Ol\u00e9n O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423\u201337. https:\/\/doi.org\/10.1007\/s10654-019-00511-8.","journal-title":"Eur J Epidemiol"},{"key":"698_CR17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1136\/annrheumdis-2024-eular.2473","volume":"83","author":"M Hameed","year":"2024","unstructured":"Hameed M, Exarchou S, Sharma A, Bergstr\u00f6m U, Einarsson JT, Turesson C. AB0944 predictors at diagnosis for initiation of biologic disease-modifying anti-rheumatic drugs in patients with spondyloarthritis. Ann Rheumatic Dis. 2024;83:1783\u201384. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.2473.","journal-title":"Ann Rheumatic Dis"},{"key":"698_CR18","doi-asserted-by":"publisher","unstructured":"Armagan B, Sari A, Erden A, Kilic L, Erdat EC, Kilickap S, et al. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: single center real life results. Med (Baltim). 2018;97(13):e 9930. https:\/\/doi.org\/10.1097\/MD.0000000000009930.","DOI":"10.1097\/MD.0000000000009930"},{"issue":"4","key":"698_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/ard-2023-224965","volume":"83","author":"S Exarchou","year":"2024","unstructured":"Exarchou S, Di Giuseppe D, Klingberg E, Sigurdardottir V, Wedr\u00e9n S, Lindstr\u00f6m U, et al. Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study. Ann Rheum Dis. 2024;83(4):446\u201356. https:\/\/doi.org\/10.1136\/ard-2023-224965.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"698_CR20","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/rheumatology\/keaa780","volume":"60","author":"C Ballegaard","year":"2021","unstructured":"Ballegaard C, Skougaard M, Guldberg-M\u00f8ller J, Nissen CV, Amris K, J\u00f8rgensen TS, et al. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatol (Oxford). 2021;60(7):3289\u2013300. https:\/\/doi.org\/10.1093\/rheumatology\/keaa780.","journal-title":"Rheumatol (Oxford)"},{"issue":"7","key":"698_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/rheumatology\/kew048","volume":"55","author":"P Putrik","year":"2016","unstructured":"Putrik P, Ramiro S, Lie E, Keszei AP, Kvien TK, van der Heijde D, et al. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (norway): results from Norwegian cohort study NOR-DMARD. Rheumatol (Oxford). 2016;55(7):1217\u201324. https:\/\/doi.org\/10.1093\/rheumatology\/kew048.","journal-title":"Rheumatol (Oxford)"},{"issue":"9","key":"698_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","volume":"17","author":"NZ Borren","year":"2019","unstructured":"Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(9):1736\u201343.e4. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.032.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"698_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard-2022-223298","volume":"82","author":"C Webers","year":"2023","unstructured":"Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landew\u00e9 RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82(1):130\u201341. https:\/\/doi.org\/10.1136\/ard-2022-223298.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00698-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00698-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:31:18Z","timestamp":1790667078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00698-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00698-w","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Swedish Ethical Review Authority (2021\u201302649; 21 June 2021). Individual informed consent from the participants was not required by the Review Authority.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohaned Hameed: Employee of UCB Pharma (starting January 27, 2025) Consultant of: Novartis. Sofia Exarchou: Consultant of: AbbVie, Amgen, Janssen, Novartis, UCB Pharma. Ankita Sharma: None declared. Ulf Bergstr\u00f6m: None declared. Jon Einarsson: None declared. Carl Turesson Speakers bureau: AbbVie, Bristol Myers-Squibb, Nordic Drugs, Pfizer, Roche, Consultant of: AbbVie, Nordic Drugs.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"75"}}